Patents by Inventor John Scheigetz

John Scheigetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Secondary amines as renin inhibitors
    Patent number: 7968720
    Abstract: The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: June 28, 2011
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Olivier Bezencon, Daniel Bur, Olivier Corminboeuf, Daniel Dube, Corinna Grisostomi, Dwight MacDonald, Dan McKay, David Powell, Lubos Remen, Sylvia Richard-Bildstein, John Scheigetz, Michel Therien, Thomas Weller
  • Cathepsin cysteine protease inhibitors
    Patent number: 7687524
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: March 30, 2010
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michael Boyd, Cheuk Lau, Christophe Mellon, Bruno Roy, John Scheigetz, Vouy Linh Truong
  • Secondary Amines as Renin Inhibitors
    Publication number: 20090176823
    Abstract: The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
    Type: Application
    Filed: January 31, 2007
    Publication date: July 9, 2009
    Inventors: Olivier Bezencon, Daniel Bur, Olivier Corminboeuf, Daniel Dube, Corinna Grisostomi, Dwight MacDonald, Dan McKay, David Powell, Lubos Remen, Sylvia Richard-Bildstein, John Scheigetz, Michel Therien, Thomas Weller
  • Cathepsin cysteine protease inhibitors
    Patent number: 7279478
    Abstract: This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: October 9, 2007
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michael Boyd, Marc Gagnon, Cheuk Lau, Christophe Mellon, John Scheigetz
  • Cathepsin cysteine protease inhibitors
    Publication number: 20070099893
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: December 9, 2004
    Publication date: May 3, 2007
    Inventors: Michael Boyd, Cheuk Lau, Christophe Mellon, Bruno Roy, John Scheigetz, Vouy Truong
  • Cathepsin cysteine protease inhibitors
    Publication number: 20060122268
    Abstract: This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I).
    Type: Application
    Filed: September 3, 2003
    Publication date: June 8, 2006
    Inventors: Michael Boyd, Marc Gagnon, Cheuk Lau, Christophe Mellon, John Scheigetz
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6486142
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Cyclopentanoindoles, compositions containing such compounds and methods of treatment
    Patent number: 6410583
    Abstract: Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: June 25, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Marc Labelle, Claudio Sturino, Bruno Roy, Carl Berthelette, Michael Boyd, Nicolas Lachance, John Scheigetz
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Publication number: 20020058644
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 16, 2002
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
    Patent number: 5424320
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: June 13, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Rejean Fortin, Yves Girard, Erich Grimm, John Hutchinson, John Scheigetz
  • Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis
    Patent number: 5360815
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: November 1, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Rejean Fortin, Yves Girard, Erich Grimm, John Hutchinson, John Scheigetz
  • Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
    Patent number: 5281720
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Yves Girard, John W. Gillard, Laird A. Trimble, John Scheigetz, James A. Yergey, Yves Ducharme, Deborah A. Nicoll-Griffith, John H. Hutchinson
  • Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis
    Patent number: 5227399
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: July 13, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Yves Girard, John W. Gillard, Laird A. Trimble, John Scheigetz, James A. Yergey, Yves Ducharme, Deborah A. Nicoll-Griffith, John H. Hutchinson
  • Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5202321
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: April 13, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John H. Hutchinson, Yves Girard, Rejean Fortin, Dwight MacDonald, John Scheigetz, Daniel Delorme, Michel Therien, Pierre Hamel
  • Benzofuran derivatives
    Patent number: 5087638
    Abstract: Benzofuran derivatives, pharmaceutical compositions and methods of treatment are disclosed. These compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders, inflammation. The compounds are also useful as analgesics and as cytoprotective agents.
    Type: Grant
    Filed: June 28, 1989
    Date of Patent: February 11, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, John Scheigetz, Joshua Rokach
  • Benzofuran derivatives useful as inhibitors of mammalian leukotriene biosynthesis
    Patent number: 4863958
    Abstract: Benzofuran derivatives, pharmaceutical compositions and methods of treatment are disclosed. These compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders, inflammation. The compounds ar also useful as analgesics and as cytoprotective agents.
    Type: Grant
    Filed: April 20, 1988
    Date of Patent: September 5, 1989
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, John Scheigetz, Joshua Rokach
  • 10,11-dihydro-dibenzo-[b,f][1,4]-thiazepin derivatives
    Patent number: 4728735
    Abstract: Compounds of the Formula I: ##STR1## are inhibitors of the mammalian 5-lipoxygenase enzyme system of the arachidonic acid cascade. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation and are useful as cytoprotective agents.
    Type: Grant
    Filed: November 10, 1986
    Date of Patent: March 1, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Patrice C. Belanger, Joshua Rokach, John Scheigetz
  • Stereospecific sulfoxidation of dibenzo thiepins
    Patent number: 4334077
    Abstract: The present invention relates to a process for the preparation of an enantiomer of 7 or 8-fluoro-dibenzo[b,f]thiepin-3-carboxylic acid having a negative rotation and prostaglandin antagonist activity.
    Type: Grant
    Filed: January 28, 1981
    Date of Patent: June 8, 1982
    Assignee: Merck & Co., Inc.
    Inventors: Patrice C. Belanger, Joshua Rokach, Robert N. Young, John Scheigetz